MX2020007944A - Nanocomplejos similares a los lípidos y sus usos. - Google Patents
Nanocomplejos similares a los lípidos y sus usos.Info
- Publication number
- MX2020007944A MX2020007944A MX2020007944A MX2020007944A MX2020007944A MX 2020007944 A MX2020007944 A MX 2020007944A MX 2020007944 A MX2020007944 A MX 2020007944A MX 2020007944 A MX2020007944 A MX 2020007944A MX 2020007944 A MX2020007944 A MX 2020007944A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- nanocomplexes
- lipid
- nanocomplex
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
- A61K49/0047—Green fluorescent protein [GFP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
A continuación, se describen compuestos de la fórmula (I): (Ver fórmula I), en donde cada una de las variables A, B, X, W, V, R1-R5, y m se definen en la presente. También se describen composiciones farmacéuticas que contienen un nanocomplejo, en donde el nanocomplejo está formado por uno de los compuestos y una proteína, un ácido nucleico o una molécula pequeña; y métodos para tratar una afección médica con una de las composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625153P | 2018-02-01 | 2018-02-01 | |
PCT/US2019/016362 WO2019152848A1 (en) | 2018-02-01 | 2019-02-01 | Lipid-like nanocomplexes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007944A true MX2020007944A (es) | 2020-11-24 |
Family
ID=67478550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007944A MX2020007944A (es) | 2018-02-01 | 2019-02-01 | Nanocomplejos similares a los lípidos y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20200368254A1 (es) |
EP (1) | EP3746129A4 (es) |
JP (1) | JP7497045B2 (es) |
KR (1) | KR20200115591A (es) |
CN (1) | CN111954542A (es) |
AU (1) | AU2019215157A1 (es) |
BR (1) | BR112020015796A2 (es) |
CA (1) | CA3089826A1 (es) |
IL (1) | IL276322A (es) |
MX (1) | MX2020007944A (es) |
WO (1) | WO2019152848A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
JP2023518295A (ja) | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状rna組成物及び方法 |
WO2021226092A1 (en) * | 2020-05-04 | 2021-11-11 | Trustees Of Tufts College | Synthetic lipid-like materials for brain delivery |
KR20240016244A (ko) * | 2021-01-15 | 2024-02-06 | 트러스티즈 오브 터프츠 칼리지 | Mrna의 표적 전달을 위한 지질 나노입자 |
CN113402404B (zh) | 2021-04-30 | 2022-03-11 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
IL308746A (en) | 2021-06-10 | 2024-03-01 | Orna Therapeutics Inc | Cyclic RNA compositions and methods |
CN113387825A (zh) * | 2021-06-10 | 2021-09-14 | 福州大学 | 长链烷基酯胺类化合物或含氟长链烷基酯胺类化合物及其公斤级制备方法 |
WO2023056033A1 (en) | 2021-09-30 | 2023-04-06 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
CA3236235A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
CN114191561B (zh) * | 2021-12-15 | 2022-08-02 | 武汉滨会生物科技股份有限公司 | 一种可离子化脂质化合物在核酸药物递送系统中的应用 |
CN114163345B (zh) * | 2021-12-15 | 2022-07-26 | 武汉滨会生物科技股份有限公司 | 一种可离子化脂质化合物及核酸体外细胞转染试剂 |
WO2023114937A2 (en) * | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Fluorinated cationic lipids for use in lipid nanoparticles |
CN116813493A (zh) * | 2022-03-21 | 2023-09-29 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
CN114716355B (zh) * | 2022-04-02 | 2023-09-05 | 华南理工大学 | 一种脂质化合物、包含其的组合物及应用 |
US20240052049A1 (en) | 2022-06-24 | 2024-02-15 | Orna Therapeutics, Inc. | Circular rna encoding chimeric antigen receptors targeting bcma |
WO2024077232A2 (en) * | 2022-10-07 | 2024-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell targeted delivery of therapeutic agents and activation of t cells |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
CN116063245A (zh) * | 2022-12-05 | 2023-05-05 | 南开大学 | 一种中心可降解的mRNA脂质体纳米粒子及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE682393C (de) * | 1933-04-14 | 1939-10-13 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung quaternaerer Stickstoffverbindungen |
US4275236A (en) * | 1979-12-26 | 1981-06-23 | Sherex Chemical Company, Inc. | Tertiary di-(β-hydroxy organo) amine oxides and their preparation |
JP4087637B2 (ja) | 2001-04-23 | 2008-05-21 | 信越化学工業株式会社 | エステル構造を有する新規第三級アミン化合物及びその製造方法 |
CA2841881A1 (en) | 2011-07-12 | 2013-01-17 | General Electric Company | Polymer and method for removing undesirable elements from aqueous solutions |
CN103131227B (zh) | 2013-02-23 | 2015-05-13 | 北京化工大学 | 一种抗生物垢涂层的制备方法 |
WO2014134445A1 (en) * | 2013-02-28 | 2014-09-04 | Tufts Unversity | Disulfide compounds for delivery of pharmaceutical agents |
US20160082126A1 (en) * | 2013-05-13 | 2016-03-24 | Tufts University | Nanocomplexes for delivery of saporin |
US9895443B2 (en) | 2013-06-26 | 2018-02-20 | Massachusetts Institute Of Technology | Multi-tailed lipids and uses thereof |
WO2017212006A1 (en) * | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
-
2019
- 2019-02-01 WO PCT/US2019/016362 patent/WO2019152848A1/en unknown
- 2019-02-01 AU AU2019215157A patent/AU2019215157A1/en active Pending
- 2019-02-01 CA CA3089826A patent/CA3089826A1/en active Pending
- 2019-02-01 CN CN201980023529.6A patent/CN111954542A/zh active Pending
- 2019-02-01 JP JP2020541571A patent/JP7497045B2/ja active Active
- 2019-02-01 KR KR1020207024651A patent/KR20200115591A/ko not_active Application Discontinuation
- 2019-02-01 BR BR112020015796-1A patent/BR112020015796A2/pt unknown
- 2019-02-01 MX MX2020007944A patent/MX2020007944A/es unknown
- 2019-02-01 EP EP19747806.8A patent/EP3746129A4/en active Pending
- 2019-02-01 US US16/966,368 patent/US20200368254A1/en active Pending
-
2020
- 2020-07-27 IL IL276322A patent/IL276322A/en unknown
-
2023
- 2023-06-02 US US18/205,096 patent/US20230405022A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230405022A1 (en) | 2023-12-21 |
BR112020015796A2 (pt) | 2021-02-09 |
CN111954542A (zh) | 2020-11-17 |
IL276322A (en) | 2020-09-30 |
JP2021512865A (ja) | 2021-05-20 |
AU2019215157A1 (en) | 2020-08-13 |
EP3746129A1 (en) | 2020-12-09 |
JP7497045B2 (ja) | 2024-06-10 |
CA3089826A1 (en) | 2019-08-08 |
US20200368254A1 (en) | 2020-11-26 |
KR20200115591A (ko) | 2020-10-07 |
EP3746129A4 (en) | 2022-03-02 |
WO2019152848A1 (en) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020007944A (es) | Nanocomplejos similares a los lípidos y sus usos. | |
MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
MX2022005839A (es) | Compuestos utiles como inhibidores de la proteina helios. | |
NO20003233L (no) | 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler | |
MX2021004707A (es) | Nuevos compuestos antihelminticos. | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
MX2020001403A (es) | Nuevos derivados de quinolina. | |
BR112021025928A2 (pt) | Métodos de preparação de ácido bempedoico e composições do mesmo | |
DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
ATE421322T1 (de) | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege | |
EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
NO20075815L (no) | Formuleringer og metoder for behandling av amyloidose | |
ATE364043T1 (de) | Pyrazolo-pyridine für die behandlung von herpes- ansteckungen | |
MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
MX2020000576A (es) | Compuestos quimicos. | |
BR112018013033A2 (pt) | compostos de indolinonas e seu uso no tratamentod de doenças fibróticas | |
MX2020011873A (es) | Nuevos derivados de quinolina. | |
AU2020231934A8 (en) | Compounds useful in HIV therapy | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
MX2021014680A (es) | Derivado de benzotriazol. | |
DE502004008819D1 (de) | Medikament zur wachstumsinhibierung von tumoren |